Hims & Hers Health Inc. Stock News

Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue in the coming years. HIMS shares surged by almost 16% on Tuesday, reaching its highest level since February.

Stay on our website for longer than five minutes and you're bound to find references to Schaeffer's Volatility Scorecard (SVS). The internal metric is a goldmine for options traders, helping identify opportunities using a scored rating of volatility expectations in the last year. But there's more to SVS than meets the eye; the hypothetical straddle trades that are foundational to SVS can be tak...

U.S. equity markets have faced significant volatility in 2025 as ongoing trade disputes, inflation uncertainty, and geopolitical tensions continue to weigh on investor sentiment. Growth-oriented companies, in particular, have seen heightened pressure, with many high-multiple stocks experiencing sharp drawdowns even amid strong underlying performance.

Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030 guidance suggests a $64 fair value per share, with potential to far exceed that price due to management's conservative guidance. I think HIMS stock's fair value is above $84 per share, with potent...

Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to the bottom, and dollars to EPS. Hims is likely a decade-plus ahead of competitors at this point with 'The Hims Trinity.'

Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth, driven by strong uptake of personalized GLP-1 offerings. Despite a projected Q2 revenue decline due to product transitions, management reaffirmed full-year 2025 revenue guidance of $2.3–2.4B and raised adj. EBITDA guidance to $295–335M. Long-term growth prospects remain strong, with a t...

Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111% YoY revenue growth and a 345% increase in net income, highlighting a sustainable and resilient business model. The company's personalized healthcare approach and new product launches, like low testos...

Hims & Hers (NYSE: HIMS) stock has been on fire in 2025, and the company just got more great news after upsizing a $450 million convertible debt offering to up to $1 billion. The growth of Hims & Hers should move overseas, and artificial intelligence will play a bigger role in its future now.